BeOne Medicines AG (BEIGF)

Market Cap	31.43B +20.7%
Revenue (ttm)	5.34B +40.2%
Net Income	286.93M
EPS	2.47
Shares Out	n/a
PE Ratio	109.54
Forward PE	48.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	5,604
Open	23.75
Previous Close	n/a
Day's Range	23.75 - 23.75
52-Week Range	15.95 - 24.92
Beta	0.52
RSI	60.51
Earnings Date	Feb 26, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 12,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF